Ontology highlight
ABSTRACT: This article contains mass spectrometry (MS) data investigating small molecule changes as an effect of a triple peroxisome proliferator-activated receptor (PPAR-pan) agonist GW625019 in the liver as described in the manuscript “PPAR-pan Activation Induces Hepatic Oxidative Stress and Lipidomic Remodelling“ [1]. Samples were analysed using liquid chromatography-mass spectrometry (LC-MS) to measure intact lipids, carnitines and selected aqueous metabolites and eicosanoids. Data files comprise of Excel (Microsoft, WA, USA) spreadsheets of identified metabolites and there area ratio values for total fatty acids, carnitines, aqueous metabolites, and eicosanoids where the intensity of the analytes were normalised to the intensity of the internal standard. In the case of open profiling intact lipid data, the Excel file contains area ratio values of retention time and mass to charge ratio pairs; again, the area ratio values were calculated by normalising to the intensity of the internal standard. It should be noted that several metabolic changes are potentially indirect (secondary, tertiary and ensuing changes). The protocols and data of eicosanoids are included in current study MTBLS278. The protocols and data of the carnitine and targeted aqueous metabolites are reported in the study MTBLS303.
INSTRUMENT(S): API 4000 QTRAP (AB Sciex)
SUBMITTER: Zsuzsanna Ament
PROVIDER: MTBLS278 | MetaboLights | 2016-05-13
REPOSITORIES: MetaboLights
Items per page: 5 1 - 5 of 6 |
Ament Zsuzsanna Z West James A JA Stanley Elizabeth E Ashmore Tom T Roberts Lee D LD Wright Jayne J Nicholls Andrew W AW Griffin Julian L JL
Free radical biology & medicine 20151130
The peroxisome proliferator-activated receptors (PPARs) are ligand activated nuclear receptors that regulate cellular homoeostasis and metabolism. PPARs control the expression of genes involved in fatty-acid and lipid metabolism. Despite evidence showing beneficial effects of their activation in the treatment of metabolic diseases, particularly dyslipidaemias and type 2 diabetes, PPAR agonists have also been associated with a variety of side effects and adverse pathological changes. Agonists hav ...[more]